
    
      This trial is conducted in patients with the refractory metastatic colorectal cancer.
      Eligible patients are randomized into two arms at 1:1 ratio to receive Irinotecan-based
      regimen or Oxaliplatin-based regimen until progress of the disease, unacceptable toxicity or
      withdrawal of consent by the patient. Study evaluation time is until death of patient or a
      deadline set by the researchers.
    
  